Back to resultsAtorvastatin in Myeloma
Primary Purpose
Myeloma
Status
Unknown status
Phase
Phase 1
Locations
Australia
Study Type
Interventional
Intervention
atorvastatin
Sponsored by
About this trial
This is an interventional treatment trial for Myeloma
Eligibility Criteria
Inclusion Criteria: Myeloma in remission Exclusion Criteria: Adverse events (AEs) to statin, already on a statin, or contraindication to statin
Sites / Locations
- Alfred Hospital
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00164086
Brief Title
Atorvastatin in Myeloma
Study Type
Interventional
2. Study Status
Record Verification Date
September 2005
Overall Recruitment Status
Unknown status
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Bayside Health
4. Oversight
5. Study Description
Brief Summary
The purpose of this trial is to study the effects of a medication already widely used to treat cardiovascular disease and diabetes, in reducing the progression of myeloma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myeloma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
atorvastatin
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Myeloma in remission
Exclusion Criteria:
Adverse events (AEs) to statin, already on a statin, or contraindication to statin
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dr Jennifer Martin, MBChB, FRACP
Phone
0405 341 676
Email
jennifer.martin@med.monash.edu.au
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Spencer, MBChB, FRACP, PhD
Organizational Affiliation
The Alfred
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alfred Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3181
Country
Australia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Martin, MBChB, FRACP
Phone
0405 341 676
Email
jennifer.martin@med.monash.edu.au
12. IPD Sharing Statement
Learn more about this trial
Atorvastatin in Myeloma
We'll reach out to this number within 24 hrs